<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04654715</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0673</org_study_id>
    <nct_id>NCT04654715</nct_id>
  </id_info>
  <brief_title>Surgical and Functional Outcomes of Rectourethral Fistulas Surgery With Gracilis Flap Interposition After Localized Prostatic Cancer Treatment.</brief_title>
  <acronym>GRA-FUR</acronym>
  <official_title>Surgical and Functional Outcomes of Rectourethral Fistulas Surgery With Gracilis Flap Interposition After Localized Prostatic Cancer Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer is the first cancer amongst men with more than 50000 cases per year in&#xD;
      France. Surgical, radiation, frost, or ultrasound induced rectourethral fistula is a rare&#xD;
      complication (&lt;1%) of localized prostatic cancer treatment but hard to manage. Different&#xD;
      types of treatment exist: conservatory, trans-sphinteric (York-Masson), transanal, perineal,&#xD;
      with or without muscle flap interposition. Gracilis flap interposition for rectourethral&#xD;
      fistula management is a promising technique but few cases are described and functional&#xD;
      results are scarce.&#xD;
&#xD;
      The aim of this study is to present surgical and functional outcomes of rectourethral&#xD;
      fistulas surgery with gracilis flap interposition after treatment of localized prostate&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Actual">November 20, 2020</completion_date>
  <primary_completion_date type="Actual">November 20, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary continence</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>Urinary Symptom Profile form (from 0 to 39), a higher score indicating a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fecal continence</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>St. Marks form (from 0 to 26), a higher score indicating a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lower extremity functional</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>No validated form exist for surgical consequences after gracilis retrieval. The form used in this study is specific (Difficulty scale for walking, kneeling, crossing the legs ; limitation of movements since the operation (yes/no and which one) (From 0 to 20), a higher score indicating a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical scarring</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>The Patient and Observer Scar Assessment Scale (From 7 to 70), a higher score indicating a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global satisfaction of the surgery</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>Patients will give a number to measure their global satisfaction of the surgery (From 1 to 10), a higher score indicating a better outcome.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">17</enrollment>
  <condition>Rectourethral Fistula</condition>
  <arm_group>
    <arm_group_label>Localized prostate cancer treatment induced rectourethral fistula</arm_group_label>
    <description>Every patient over 18 years old operated for closure of a rectourethral fistula with gracilis flap interposition after localized prostatic cancer treatment (Radiotherapy, surgery, cryotherapy and HIFU).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gracilis flap interposition for rectouretral fistula management</intervention_name>
    <description>Gracilis flap interposition is a surgery for rectouretral fistula</description>
    <arm_group_label>Localized prostate cancer treatment induced rectourethral fistula</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male patients over 18 that have been treated for a localized prostatic cancer and who were&#xD;
        affected with a treatment-induced rectourethral fistula&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male over 18 years old&#xD;
&#xD;
          -  Treated for a localized prostatic cancer (Prostatectomy, cryotherapy, HIFU,&#xD;
             radiotherapy)&#xD;
&#xD;
          -  Affected with a treatment induced Rectourethral fistula&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Rectourethral fistula caused by other pelvic diseases (gynecological or digestif&#xD;
             cancer, inflammatory bowel disease, other urogenital issues)&#xD;
&#xD;
          -  Rectourethral fistula treated by cysto-prostatectomy with urinary tract derivation&#xD;
&#xD;
          -  Patient under guardianship&#xD;
&#xD;
          -  Non comprehension of written or spoken French&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rectourethral fistula</keyword>
  <keyword>Gracilis flap</keyword>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

